You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches: features and perspectives
|
|---|---|
| Published in |
Orphanet Journal of Rare Diseases, February 2014
|
| DOI | 10.1186/1750-1172-9-20 |
| Pubmed ID | |
| Authors |
David Uguen, Thomas Lönngren, Yann Le Cam, Sarah Garner, Emmanuelle Voisin, Carlo Incerti, Marc Dunoyer, Moncef Slaoui |
| Abstract |
There is growing recognition that the current research-and-development (R&D) and innovation-regulation ecosystem could be made more efficient to stimulate and support access to innovative therapies for those patients with rare, life-threatening diseases for which there are no adequate licensed therapies. New and progressive thinking on the principles and processes of drug development and regulation are needed in rare disease settings in order to ensure developments are financially sustainable. This paper presents perspectives on the current and emerging schemes for accelerating development of and access to medicines for rare diseases in the European Union. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 22% |
| United Kingdom | 1 | 11% |
| Canada | 1 | 11% |
| Unknown | 5 | 56% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 56% |
| Scientists | 3 | 33% |
| Practitioners (doctors, other healthcare professionals) | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 3% |
| Brazil | 1 | 3% |
| Unknown | 32 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 35% |
| Student > Ph. D. Student | 5 | 15% |
| Student > Bachelor | 4 | 12% |
| Researcher | 3 | 9% |
| Other | 2 | 6% |
| Other | 6 | 18% |
| Unknown | 2 | 6% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 50% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 12% |
| Nursing and Health Professions | 3 | 9% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Social Sciences | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 3 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 October 2023.
All research outputs
#4,139,649
of 25,374,647 outputs
Outputs from Orphanet Journal of Rare Diseases
#567
of 3,105 outputs
Outputs of similar age
#47,645
of 327,779 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#9
of 42 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,105 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,779 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.